Milestone Payments, Clinical Trial Results, Technical Updates, and Earnings Results - Analyst Notes on Pharmacyclics, Isis, Novo Nordisk, Dr. Reddy's and Orexigen
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Pharmacyclics Inc. (NASDAQ: PCYC), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Novo Nordisk A/S (NYSE: NVO), Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and Orexigen Therapeutics, Inc. (NASDAQ: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3053-100free.
--
Pharmacyclics Inc. Analyst Notes
On May 23, 2014, Pharmacyclics, Inc. (Pharmacyclics) stock ended the day at $87.62 compared to the previous closing price of $94.56, representing a 7.34% decrease. On the same day, the Company had disclosed in a filing that Paula Boultbee, Executive Vice President, Sales and Marketing, resigned effective May 20, 2014. Paula recently worked together with the Company's collaboration partner Janssen on IMBRUVICA related non-US commercial strategies. The Company's stock decreased 10.61% over the past five trading days compared to the Nasdaq Composite which rose 2.33% during the same trading period. The full analyst notes on Pharmacyclics are available to download free of charge at:
http://www.analystsreview.com/PCYC.pdf/Register
--
Isis Pharmaceuticals, Inc. Analyst Notes
On May 15, 2014, Isis Pharmaceuticals, Inc. (Isis) announced that it has successfully earned a total of $3.0 million worth of milestone payment from GlaxoSmithKline (GSK). The Company informed that the earnings are related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. B. Lynne Parshall, Chief Operating Officer at Isis commented, "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our pipeline, including ISIS-TTRRx, which is currently in Phase 3 development. The payment we earned today is further evidence of this productive collaboration." Isis stated that the collaboration with GlaxoSmithKline mainly focuses on leveraging antisense technology to develop drugs to treat rare and infectious diseases. The full analyst notes on Isis are available to download free of charge at:
http://www.analystsreview.com/ISIS.pdf/Register
--
Novo Nordisk A/S Analyst Notes
On May 12, 2014, Novo Nordisk A/S (Novo Nordisk) announced new phase 3 interim data from its Guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa) which shows that NovoEight® provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment. According to the Company, NovoEight® is the first new rFVIII molecule in over a decade. Novo Nordisk stated that the results showed that NovoEight® has successfully demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients. Dr Margareth Ozelo, Hemocentre, IHTC, University of Campinas, Sao Paulo, Brazil and guardian™2 investigator said, "As a physician treating haemophilia A, having another FVIII product available is good news and can lead to improved treatment outcomes and quality of life for our patients." The full analyst notes on Novo Nordisk are available to download free of charge at:
http://www.analystsreview.com/NVO.pdf/Register
--
Dr. Reddy's Laboratories Ltd. Analyst Notes
On May 13, 2014, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) reported its consolidated Q4 FY 2014 and FY 2014 financial results (period ended March 31, 2014). For the quarter, the Company reported revenues of $580 million compared to $557 million in Q4 FY 2013. According to the Company, revenue growth was largely driven by its North American segment in which there were key launches in limited competition space, progress on market share expansion of key molecules and 13 product fillings in the U.S. Profit for the quarter stood at $80 million versus $95 million in Q4 FY 2013. Diluted EPS were $0.47 per share compared to $0.56 in Q4 FY 2013. For FY 2014, revenues totaled $2.2 billion compared to $1.9 billion in FY 2013. Profit for the year stood at $359 million versus $280 million in FY 2013. Diluted EPS were $2.10 compared to $1.64 in FY 2013. The full analyst notes on Dr. Reddy's are available to download free of charge at:
http://www.analystsreview.com/RDY.pdf/Register
--
Orexigen Therapeutics, Inc. Analyst Notes
On May 23, 2014, Orexigen Therapeutics, Inc. (Orexigen) stock ended the day at $5.71 compared to the previous day's closing price at $5.42, up by 5.35%. The Company's stock rose 5.74% over the past three trading days compared to the Nasdaq Composite which rose 2.17% during the same trading period. The full analyst notes on Orexigen are available to download free of charge at:
http://www.analystsreview.com/OREX.pdf/Register
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article